AB 2086: Controlled substances: CURES database.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-09-06
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance.
This bill would allow prescribers to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance.
This bill would allow prescribers to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance.
This bill would allow prescribers to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance.
This bill would allow prescribers to request from the Department of Justice access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
Existing law classifies certain controlled substances into designated schedules. Existing law requires the Department of Justice to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by a health care practitioner authorized to prescribe, order, administer, furnish, or dispense a Schedule II, Schedule III, or Schedule IV controlled substance.
This bill would allow prescribers to request from the Department of Justice a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
A prescriber shall be allowed to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
A prescriber shall be allowed to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
A prescriber shall be allowed to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
SECTION 1.Section 11165 of the Health and Safety Code is amended to read:11165.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.(C)A prescriber shall be allowed to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.(4)National Drug Code (NDC) number of the controlled substance dispensed.(5)Quantity of the controlled substance dispensed.(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.(7)Number of refills ordered.(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.(9)Date of origin of the prescription.(10)Date of dispensing of the prescription.(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(C)A prescriber may request from the Department of Justice shall be allowed to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
(a)To assist health care practitioners in their efforts to ensure appropriate prescribing, ordering, administering, furnishing, and dispensing of controlled substances, law enforcement and regulatory agencies in their efforts to control the diversion and resultant abuse of Schedule II, Schedule III, and Schedule IV controlled substances, and for statistical analysis, education, and research, the Department of Justice shall, contingent upon the availability of adequate funds in the CURES Fund, maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for the electronic monitoring of, and Internet access to information regarding, the prescribing and dispensing of Schedule II, Schedule III, and Schedule IV controlled substances by all practitioners authorized to prescribe, order, administer, furnish, or dispense these controlled substances.
(b)The Department of Justice may seek and use grant funds to pay the costs incurred by the operation and maintenance of CURES. The department shall annually report to the Legislature and make available to the public the amount and source of funds it receives for support of CURES.
(c)(1)The operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations.
(2)(A)CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party, unless authorized by, or pursuant to, state and federal privacy and security laws and regulations. The Department of Justice shall establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES, consistent with this subdivision.
(B)Notwithstanding subparagraph (A), a regulatory board whose licensees do not prescribe, order, administer, furnish, or dispense controlled substances shall not be provided data obtained from CURES.
(C)A prescriber may request from the Department of Justice a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
(3)In accordance with federal and state privacy laws and regulations, a health care practitioner may provide a patient with a copy of the patients CURES patient activity report as long as no additional CURES data is provided and keep a copy of the report in the patients medical record in compliance with subdivision (d) of Section 11165.1.
(d)For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:
(1)Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
(2)The prescribers category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
(3)Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
(4)National Drug Code (NDC) number of the controlled substance dispensed.
(5)Quantity of the controlled substance dispensed.
(6)International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
(7)Number of refills ordered.
(8)Whether the drug was dispensed as a refill of a prescription or as a first-time request.
(9)Date of origin of the prescription.
(10)Date of dispensing of the prescription.
(e)The Department of Justice may invite stakeholders to assist, advise, and make recommendations on the establishment of rules and regulations necessary to ensure the proper administration and enforcement of the CURES database. All prescriber and dispenser invitees shall be licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, in active practice in California, and a regular user of CURES.
(f)The Department of Justice shall, prior to upgrading CURES, consult with prescribers licensed by one of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, one or more of the boards or committees identified in subdivision (d) of Section 208 of the Business and Professions Code, and any other stakeholder identified by the department, for the purpose of identifying desirable capabilities and upgrades to the CURES Prescription Drug Monitoring Program (PDMP).
(g)The Department of Justice may establish a process to educate authorized subscribers of the CURES PDMP on how to access and use the CURES PDMP.
|
Date
|
Status
|
|---|---|
| Sep 6, 2018 | Chaptered by Secretary of State - Chapter 274, Statutes of 2018. |
| Sep 6, 2018 | Approved by the Governor. |
| Aug 28, 2018 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 23, 2018 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 20, 2018 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 22 pursuant to Assembly Rule 77. |
| Aug 20, 2018 | Read third time. Passed. Ordered to the Assembly. |
| Aug 15, 2018 | Read second time. Ordered to third reading. |
| Aug 14, 2018 | Read third time and amended. Ordered to second reading. |
| Aug 6, 2018 | From Consent Calendar. |
| Jul 3, 2018 | Read second time. Ordered to Consent Calendar. |
| Jul 2, 2018 | From committee: Be ordered to second reading file pursuant to Senate Rule 28.8 and ordered to Consent Calendar. |
| Jun 19, 2018 | From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 9. Noes 0.) (June 18). Re-referred to Com. on APPR. |
| May 17, 2018 | Referred to Com. on B., P. & E.D. |
| May 3, 2018 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 3, 2018 | Read third time. Passed. Ordered to the Senate. |
| Apr 26, 2018 | Read second time. Ordered to Consent Calendar. |
| Apr 25, 2018 | From committee: Do pass. To Consent Calendar. (Ayes 17. Noes 0.) (April 25). |
| Apr 10, 2018 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 10). Re-referred to Com. on APPR. |
| Apr 4, 2018 | Re-referred to Com. on B. & P. |
| Apr 3, 2018 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Feb 22, 2018 | Referred to Com. on B. & P. |
| Feb 8, 2018 | From printer. May be heard in committee March 10. |
| Feb 7, 2018 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 23, 2018 | AB 2086 GALLAGHER Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 20, 2018 | Assembly 3rd Reading AB2086 Gallagher et al. By Hernandez | Senate Floor |
Passed |
|
| Jun 18, 2018 | Do pass, but first be re-referred to the Committee on [Appropriations] with the recommendation: To Consent Calendar | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| May 3, 2018 | AB 2086 GALLAGHER Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Apr 25, 2018 | Do pass. To Consent Calendar. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 10, 2018 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2086
Author:(Gallagher)
As Amended Ver:August 14, 2018
Majority vote
ASSEMBLY: | 71-0 | (May 3, 2018) | SENATE: | 39-0 | (August 20, 2018) |
Original Committee Reference: B. & P.
SUMMARY: Allows prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber in the California Department of Justice (DOJ)'s prescription drug monitoring program (PDMP).
The Senate amendments resolve potential chaptering issues by moving the bill's provisions into a newly created code section.
EXISTING LAW:
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES), a PDMP maintained by the DOJ for the purposes of collecting records of dispensed controlled substances for review by licensed prescribers and dispensers, regulatory investigators, law enforcement, and statistical researchers. (Health and Safety Code Section (HSC) 11165(a))
- Requires pharmacists and other dispensers to report information to CURES within 7 days relating to prescriptions of Schedule II, III, and IV controlled substances. (HSC 11165(d))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) certificate providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC 11165.1(a))
- Beginning October 2, 2018, requires certain health care practitioners to consult the CURES database to review a patient's controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC 11165.4)
- Requires the DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC 11165.1)
- Provides dedicated funding for the CURES program through an annual license fee of $6 assessed for licensees authorized to prescribe or dispense controlled substances in California. (Business and Professions Code Section (BPC) 208)
- Authorizes the DOJ to seek voluntarily contributed private funds from insurers, health care service plans, qualified manufacturers, and other donors for the purpose of supporting CURES. (HSC 11165.5)
- Allows the DOJ to conduct audits of CURES and its users and issue citations and fines for system misuse. (HSC 11165.2)
- Requires the CURES database to comply with all applicable federal and state privacy and security laws and regulations and requires the DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC 11165(c))
FISCAL EFFECT: According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, negligible state costs..
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
The opioid epidemic is a public health crisis that affects every community. Addressing it will take a multi-pronged approach that includes education, treatment, and prevention. It also includes keeping pills out of the hands of people who shouldn't have them, and AB 2086 will do this by helping us identify fraudulent prescriptions. AB 2086 will help prevent fraudulent prescriptions of controlled substances by allowing prescribers to request a list of patients for whom they are listed as being the prescriber in the CURES database.
Background. Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the acquired immunodeficiency syndrome (AIDS) epidemic.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
CURES Database. CURES was first established in 1996 as a "technologically sophisticated" database containing prescription records collected through California's Triplicate Prescription Program, which provided the DOJ with copies of all Schedule II drug prescriptions. Subsequent legislation made CURES the state's sole prescription record repository and added Schedule III and IV drugs to the database. In 2008, CURES was upgraded to function as a PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient's prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee's prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion. Over 50 million prescription records have been uploaded into the system by dispensing pharmacists since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users.
Beginning six months from a to-be-announced date of certification by the Attorney General, health practitioners will be required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed. Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements. As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
Prescriber Access to Prescription Records. Statute is somewhat nonspecific in regards to how data in CURES may be accessed by authorized users. The DOJ is required to "establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES." To date, the majority of CURES access policies are not memorialized in regulations or codified in statute. Access to the database is preceded by acceptance of a user agreement that does outline certain parameters of system misuse. Beyond that, health practitioners logging into CURES are required to comply with "all applicable federal and state privacy and security laws and regulations."
CURES is additionally required by statute generally to "operate under existing provisions of law to safeguard the privacy and confidentiality of patients." In addition to the federal Health Insurance Portability and Accountability Act (HIPAA) and any constitutional protections of privacy, there are several state statutes specifically believed to apply to CURES. The DOJ has historically interpreted the Information Practices Act as applicable to the database, which governs how state agencies must generally handle personal information. The California Medical Information Act, which limits the disclosure of medical information by health entities, is widely believed to apply to the disclosure of data in CURES. State medical information laws regarding patient access to health records also give individuals a right to receive copies of information about them contained in CURES.
In the past, the DOJ has stated that it does not believe it has statutorily authority to allow health practitioners to request their own physician activity report for purposes of reviewing patients affiliated with them in CURES. This access is desirable to practitioners because it would enable them to identify unknown patients alleging that they had received a prescription from the practitioner's office, suggesting possible fraud for which the practitioner may be unknowingly held liable. Because there is nothing clearly permitting that this use of the system is permitted within the access parameters that exist within statute, the medical professional community has advocated for clarification.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0004051
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 2086
Amended: 8/14/18 in Senate
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 6/18/18
AYES: Hill, Fuller, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 71-0, 5/3/18 (Consent) - See last page for vote
DIGEST:
This bill authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
Senate Floor Amendments of 8/14/18 eliminate chaptering conflicts with other bills making changes to the statutes governing the CURES database.
Existing law:
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, naturopathic doctor (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), certified nurse midwife (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the certified nurse midwife’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), nurse practitioner (if it is consistent with a nurse practitioner’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or physician assistant acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Establishes the Controlled Substances Utilization Review and Evaluation System (CURES) for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Authorizes a health care practitioner to provide a patient with a copy of the patient’s CURES patient activity report as long as no additional CURES data is provided and authorizes a health care practitioner to keep a copy of the report in the patient’s medical record. (HSC § 11165 (c)(3))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
This bill authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
Background
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, and pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Comments
According to the author, “The abuse of opioids, including prescription pain relievers, is a national crisis. Overdoses are now the leading cause of death of Americans under age 50. Fraudulent prescriptions contribute to this problem. In one case, a drug ring obtained over $50,000 in oxycodone pills using a stolen prescription pad. In another case, stolen prescription pads were used to obtain more than 25,000 oxycodone pills and 30,000 hydrocodone pills.” The author notes that “doctors can only pull up individual patients to check that patient’s prescription history. Additionally, even though physicians must report stolen prescription pads (which are also published), it is difficult for them to determine if their stolen pad has been used.”
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
America’s Physician Group
California Academy of Family Physicians
California Chiropractic Association
California Dental Association
California District Attorneys Association
CaliforniaHealth+ Advocates
California Hospital Association
California Medical Association
California Police Chiefs Association
California Society of Addiction Medicine
California Society of Anesthesiologists
Dental Board of California
McKesson Corporation
Medical Board of California
None received
ARGUMENTS IN SUPPORT: Supporters believe that this bill provides prescribers with a simple tool for checking to see if a patient is presenting fraudulent prescriptions that falsely identify the provider as their prescriber. According to the California Academy of Family Physicians, allowing review of prescription history to verify accuracy will help prescribers flag and report suspicious prescriptions that they may not have actually written. The California Chiropractic Association states that currently prescribers have difficulty identifying whether a patient has been presenting fraudulent or forged prescriptions from a health professional who has not actually written a prescription for that patient. CaliforniaHealth+ Advocates notes that this bill will potentially prevent diversion and reduce provider shopping and prescription fraud. The California Medical Association states that this bill advances the organization’s efforts of making CURES as user-oriented and effective as possible.
ASSEMBLY FLOOR: 71-0, 5/3/18
AYES: Acosta, Aguiar-Curry, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Eggman, Flora, Fong, Frazier, Friedman, Gallagher, Eduardo Garcia, Gipson, Gloria, Gonzalez Fletcher, Gray, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Travis Allen, Caballero, Choi, Cristina Garcia, Grayson, Quirk-Silva, Voepel
8/15/18 14:32:36
**** END ****
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 2086
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 6/18/18
AYES: Hill, Fuller, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 71-0, 5/3/18 (Consent) - See last page for vote
DIGEST:
This bill authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
Existing law:
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, naturopathic doctor (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), certified nurse midwife (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the certified nurse midwife’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), nurse practitioner (if it is consistent with a nurse practitioner’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or physician assistant acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Establishes the Controlled Substances Utilization Review and Evaluation System (CURES) for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Authorizes a health care practitioner to provide a patient with a copy of the patient’s CURES patient activity report as long as no additional CURES data is provided and authorizes a health care practitioner to keep a copy of the report in the patient’s medical record. (HSC § 11165 (c)(3))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
This bill authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
Background
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, and pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Comments
According to the author, “The abuse of opioids, including prescription pain relievers, is a national crisis. Overdoses are now the leading cause of death of Americans under age 50. Fraudulent prescriptions contribute to this problem. In one case, a drug ring obtained over $50,000 in oxycodone pills using a stolen prescription pad. In another case, stolen prescription pads were used to obtain more than 25,000 oxycodone pills and 30,000 hydrocodone pills.” The author notes that “doctors can only pull up individual patients to check that patient’s prescription history. Additionally, even though physicians must report stolen prescription pads (which are also published), it is difficult for them to determine if their stolen pad has been used.”
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
America’s Physician Group
California Academy of Family Physicians
California Chiropractic Association
California Dental Association
California District Attorneys Association
CaliforniaHealth+ Advocates
California Hospital Association
California Medical Association
California Police Chiefs Association
California Society of Addiction Medicine
California Society of Anesthesiologists
Dental Board of California
McKesson Corporation
Medical Board of California
None received
ARGUMENTS IN SUPPORT: Supporters believe that this bill provides prescribers with a simple tool for checking to see if a patient is presenting fraudulent prescriptions that falsely identify the provider as their prescriber. According to the California Academy of Family Physicians, allowing review of prescription history to verify accuracy will help prescribers flag and report suspicious prescriptions that they may not have actually written. The California Chiropractic Association states that currently prescribers have difficulty identifying whether a patient has been presenting fraudulent or forged prescriptions from a health professional who has not actually written a prescription for that patient. CaliforniaHealth+ Advocates notes that this bill will potentially prevent diversion and reduce provider shopping and prescription fraud. The California Medical Association states that this bill advances the organization’s efforts of making CURES as user-oriented and effective as possible.
ASSEMBLY FLOOR: 71-0, 5/3/18
AYES: Acosta, Aguiar-Curry, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chávez, Chen, Chiu, Chu, Cooley, Cooper, Cunningham, Dahle, Daly, Eggman, Flora, Fong, Frazier, Friedman, Gallagher, Eduardo Garcia, Gipson, Gloria, Gonzalez Fletcher, Gray, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Travis Allen, Caballero, Choi, Cristina Garcia, Grayson, Quirk-Silva, Voepel
8/8/18 9:53:54
**** END ****
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2017 - 2018 Regular
Bill No: Hearing Date: June 18, 2018
Author: | |||
Version: | April 3, 2018 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Sarah Mason | ||
Subject:
SUMMARY: Authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
Existing law:
- Establishes various practice acts in the Business and Professions Code (BPC) governed by various boards within the Department of Consumer Affairs (DCA) which provide for the licensing and regulation of health care professionals including: physicians and surgeons (under the Medical Practice Act), dentists (under the Dental Practice Act), veterinarians (under the Veterinary Medicine Practice Act); registered nurses, nurse practitioners (NP) and certified nurse-midwives (CNM) (under the Nursing Practice Act); physician assistants (PA) (under the Physician Assistant Practice Act); osteopathic physicians and surgeons (under the Osteopathic Medical Practice Act); naturopathic doctors (ND) (under the Naturopathic Doctors Act); optometrists (under the Optometry Practice Act); doctors of podiatric medicine (under the Podiatric Act) and; pharmacies, pharmacists and wholesalers of dangerous drugs or devices (under the Pharmacy Law). (Business and Professions Code (BPC) §§ 500, et seq.)
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or ND. (BPC § 4059)
- Establishes the Uniform Controlled Substances Act which regulates controlled substances and defines an opiate as any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. (Health and Safety Code (HSC) § 11020)
- Classifies controlled substances into five schedules according to their danger and potential for abuse. (HSC §§ 11054-11058)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), CNM (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), NP (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or PA acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance.
(HSC § 11150) - Establishes CURES for the electronic monitoring of Schedule II, III and IV controlled substance prescriptions. CURES provides for the electronic transmission of Schedule II, III and IV controlled substance prescription information to the Department of Justice (DOJ) no more than seven days from the time prescriptions are dispensed. (HSC § 11165)
- States that the purpose of CURES is to assist law enforcement and regulatory agencies in controlling diversion and abuse of Schedule II, III and IV controlled substances and for statistical analysis, education, and research. (HSC § 11165 (a))
- Establishes privacy protections for patient data and specifies that the operation of CURES shall comply with all applicable federal and state privacy and security laws and regulations. Specifies that CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Specifies that data obtained from CURES can only be accessed by appropriate state, local, and federal persons or public agencies for disciplinary, civil, or criminal actions. Specifies that CURES data shall also only be provided, as determined by DOJ, to other agencies or entities for educating practitioners and others, in lieu of disciplinary, civil or criminal actions. Authorizes non-identifying CURES data to be provided to public and private entities for education, research, peer review, and statistical analysis. Requires DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165 (c) (1) and (c) (2) (A))
- Requires DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) registration providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Authorizes a health care practitioner to provide a patient with a copy of the patient’s CURES patient activity report as long as no additional CURES data is provided and authorizes a health care practitioner to keep a copy of the report in the patient’s medical record. (HSC § 11165 (c)(3))
- Requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
- Establishes, pursuant to the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), certain requirements relating to the provision of health insurance, including provisions relating to the confidentiality of health records. HIPAA prohibits a covered entity that uses electronic means to perform HIPAA-covered transactions, from using or disclosing personal health information except pursuant to a written authorization signed by the patient or for treatment, payment, or health care operations. Notwithstanding those provisions, HIPAA allows a covered entity to maintain a directory of patients in its facility for specified purposes, and to disclose the protected health information of a patient to family members, relatives, or other persons identified by the patient, if certain conditions are met. Covered entities include health plans, health care clearinghouses, such as billing services and community health information systems, and health care providers that transmit health care data in a way that is regulated by HIPAA. HIPAA further provides that if its provisions conflict with a provision of state law, the provision that is most protective of patient privacy prevails. (Public Law 104–191, 104th Congress)
- Prohibits, pursuant to the state Confidentiality of Medical Information Act (CMIA), a provider of health care, a health care service plan, a contractor, a corporation and its subsidiaries and affiliates, or any business that offers software or hardware to consumers, including a mobile application or other related device, as defined, from intentionally sharing, selling, using for marketing, or otherwise using any medical information, as defined, for any purpose not necessary to provide health care services to a patient, except as expressly authorized by the patient, enrollee, or subscriber, as specified, or as otherwise required or authorized by law. A violation of the provisions of this act that results in economic loss or personal injury to a patient is a crime. (Civil Code Sections (CIV) 56, et seq.)
- Defines, for purposes of the CMIA, “medical information” to mean “any individually identifiable information, in electronic or physical form, in possession of or derived from a provider of health care, health care service plan, pharmaceutical company, or contractor regarding a patient’s medical history, mental or physical condition, or treatment.” “Individually identifiable” means that the medical information includes or contains any element of personal identifying information sufficient to allow identification of the individual, such as the patient’s name, address, electronic mail address, telephone number, or social security number, or other information that, alone or in combination with other publicly available information, reveals the individual’s identity.” (CIV § 56.05(g))
This bill authorizes a prescriber of controlled substances to review a list of patients for whom they are listed as being the prescriber.
FISCAL EFFECT:
This bill is keyed fiscal by Legislative Counsel. According to the Assembly Committee on Appropriations analysis dated April 25, 2018, this bill will result in one-time information technology costs to DOJ in the range of $35,000 General Fund monies to allow prescribers to run this new type of report.
COMMENTS:
- Purpose. The Author is the Sponsor of this bill. According to the Author, “The abuse of opioids, including prescription pain relievers, is a national crisis. Overdoses are now the leading cause of death of Americans under age 50. Fraudulent prescriptions contribute to this problem. In one case, a drug ring obtained over $50,000 in oxycodone pills using a stolen prescription pad. In another case, stolen prescription pads were used to obtain more than 25,000 oxycodone pills and 30,000 hydrocodone pills.” The Author notes that “doctors can only pull up individual patients to check that patient’s prescription history. Additionally, even though physicians must report stolen prescription pads (which are also published), it is difficult for them to determine if their stolen pad has been used.”
According to the Author, “Unfortunately, the DOJ has stated that it does not believe it has statutory authority to allow prescribers to access their own prescribing history via CURES. This makes it difficult for prescribers to identify whether a patient has been presenting fraudulent or forged prescriptions from a health professional who has not actually written a prescription for that patient.”
- Controlled Substances, PDMPs, and CURES. Through the Controlled Substances Act of 1970, the federal government regulates the manufacture, distribution, and dispensing of controlled substances. The Act ranks into five schedules those drugs known to have potential for physical or psychological harm, based on three considerations: (a) their potential for abuse; (b) their accepted medical use; and, (c) their accepted safety under medical supervision.
Schedule I controlled substances have a high potential for abuse and no generally accepted medical use such as heroin, ecstasy, and LSD.
Schedule II controlled substances have a currently accepted medical use in treatment, or a currently accepted medical use with severe restrictions, and have a high potential for abuse and psychological or physical dependence. Schedule II drugs can be narcotics or non-narcotic. Examples of Schedule II controlled substances include combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), morphine, methadone, Ritalin, Demerol, Percocet, Percodan, fentanyl, and Oxycontin.
Schedule III and IV controlled substances have a currently accepted medical use in treatment, less potential for abuse but are known to be mixed in specific ways to achieve a narcotic-like end product. Examples include Tylenol with codeine, testosterone, Xanax, Ambien, and other anti-anxiety drugs.
Schedule V drugs have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes.
With rising levels of prescription drug abuse, prescription drug monitoring programs (PDMPs) assist law enforcement and regulatory bodies with their efforts to reduce drug abuse and diversion. In California, CURES is an electronic tracking program that reports all pharmacy (and specified types of prescriber) dispensing of certain schedules of controlled drugs by drug name, quantity, prescriber, patient, and pharmacy. Data from CURES is managed by DOJ. Information tracked in CURES contains the patient name, prescriber name, pharmacy name, drug name, amount and dosage, and is available to law enforcement agencies, regulatory bodies, prescribers, dispensers, and qualified researchers. CURES provides information to identify if a person is “doctor shopping” (when a patient, often a prescription-drug addict, visits multiple doctors to obtain multiple prescriptions for drugs, or uses multiple pharmacies to obtain prescription drugs). The system can also report on the top drugs prescribed for a specific time period, drugs prescribed in a particular county, doctor prescribing data, pharmacy dispensing data, and is a critical tool for assessing whether multiple prescriptions for the same patient may exist.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists and other dispensers are required to report basic information about the patient and their prescription within seven days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensers since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Health practitioners will soon be required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed (DOJ certified the system for statewide use on March 31, 2017; consultation requirements for prescribers outlined in SB 482 [Lara, Chapter 708, Statutes of 2016] take effect six months after DOJ certifies the system). Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
- Related Legislation This Year. CURES has been the focus of ongoing discussions in the Legislature as California and the nation face an epidemic of prescription drug abuse and related overdose deaths.
SB 1240 (Stone) would expande the drugs required to be reported and monitored in CURES to include all dangerous drugs and Schedule V controlled substances and requires inclusion of a description of the diagnosis, condition, or purpose for which the prescription was issued and the directions for use to the list of information pharmacies are required to report to CURES for each prescription. (Status: This bill is also pending in this committee.)
AB 1751 (Low) would provide a framework for CURES to connect with other states that comply with California’s patient privacy and data security standards. (Status: This bill is also pending in this committee.)
AB 1752 (Low) would add Schedule V drugs to CURES, changes the required timeframe in which pharmacists are required to report dispensed prescriptions from seven days to the following business day, and makes other technical changes. (Status: This bill is also pending in this committee.)
AB 1753 (Low) would limit the number of security printers authorized to manufacture prescription pads and linking uniquely serialized pads with CURES. (Status: This bill is also pending in this committee.)
AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance schedules. (Status: The bill is pending in the Senate Committee on Public Safety.)
AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions. (Status: This bill is also pending in this committee.)
- Prior Related Legislation. AB 40 (Santiago, Chapter 607, Statutes of 2017) authorized an entity that operates a health information technology system to establish an integration with, and submit queries to CURES on either a user-initiated basis or automated basis, according to certain requirements.
SB 641 (Lara) of 2016 would have prohibited the DOJ from releasing data in CURES to a law enforcement agency except pursuant to a warrant. (Status: The measure did not move from the Assembly Committee on Public Safety.)
SB 482 (Lara, Chapter 708, Statutes of 2016) required a health care provider authorized to prescribe, order, administer, or furnish a controlled substance to consult CURES prior to prescribing a Schedule II, III or IV drug to a patient for the first time and at least once every four months thereafter if the substance remains part of the patient’s treatment. The bill provided exemptions from the responsibility to consult the CURES system, including while a patient is admitted to a certain type of facility, if a patient receives a non-refillable five-day supply or less prescription in conjunction with a surgery, and in the event of a technological failure or inability to access the CURES system.
SB 1258 (DeSaulnier) of 2014 would have made several changes to the ways that controlled substances are prescribed and tracked in the CURES and would have required medical providers to use electronic prescribing systems, would have required additional reporting of controlled substance prescribing, and would have placed additional restrictions on the prescribing of controlled substances.
(Status: The bill was held in the Senate Committee on Appropriations.)
SB 809 (De Saulnier, Chapter 400, Statutes of 2013) established a funding mechanism to update and maintain CURES, required all prescribing health care practitioners to apply to access CURES information, and established processes and procedures for regulating prescribing licensees through CURES and securing private information.
SB 151 (Burton, Chapter 406, Statutes of 2003) made the CURES program permanent.
AB 2655 (Matthews, Chapter 345, Statutes of 2002) extended the CURES program to 2008 and provided access to CURES data by licensed health care providers.
SB 1308 (Committee on Business and Professions, Chapter 655, Statutes of 1999) extended the sunset date on the CURES program to July 1, 2003 and required DOJ to submit annual status reports on the program to the Legislature.
AB 3042 (Takasugi, Chapter 738, Statutes of 1996) established a three year pilot program, beginning in July 1997, for the electronic monitoring of prescribing and dispensing of Schedule II controlled substances.
- Arguments in Support. Supporters believe that this bill provides prescribers with a simple tool for checking to see if a patient is presenting fraudulent prescriptions that falsely identify the provider as their prescriber. According to the California Academy of Family Physicians, allowing review of prescription history to verify accuracy will help prescribers flag and report suspicious prescriptions that they may not have actually written. The California Chiropractic Association states that currently prescribers have difficulty identifying whether a patient has been presenting fraudulent or forged prescriptions from a health professional who has not actually written a prescription for that patient. CaliforniaHealth+ Advocates notes that this bill will potentially prevent diversion and reduce provider shopping and prescription fraud. The California Medical Association states that this bill advances the organization’s efforts of making CURES as user-oriented and effective as possible.
SUPPORT AND OPPOSITION:
Support:
America’s Physician Group
California Academy of Family Physicians
California Chiropractic Association
California Dental Association
California District Attorneys Association
CaliforniaHealth+ Advocates
California Hospital Association
California Medical Association
California Police Chiefs Association
California Society of Addiction Medicine
California Society of Anesthesiologists
Dental Board of California
McKesson Corporation
Medical Board of California
Opposition:
None on file as of June 13, 2018.
-- END --
Date of Hearing: April 25, 2018
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez Fletcher, Chair
ABPCA Bill Id:AB 2086
Author:(Gallagher) – As Amended Ver:April 3, 2018
Policy Committee: | Business and Professions | Vote: | 16 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill allows prescribers of controlled substances to review a list of patients for whom they are listed as the prescriber in the California Department of Justice (DOJ)’s prescription drug monitoring program (PDMP), also known as CURES (Controlled Substance Utilization Review and Evaluation System).
FISCAL EFFECT:
One-time information technology costs to DOJ in the range of $35,000 GF to allow prescribers to run this new type of report.
COMMENTS:
- Purpose. This author-sponsored bill intends to offer physicians a means to verify patients for whom they are listed as a prescriber are, in fact, patients for whom they have prescribed drugs. Currently, the CURES database can be queried in other ways but does not include this function. The author indicates this will help curb prescription drug fraud and abuse, including that related to prescription opioids.
- Background. Prescription drug monitoring programs are considered critical in the effort to curb prescription drug abuse. The state system, CURES, allows health professionals, regulators, and law enforcement personnel to conduct web-based searches of prescription drug data in order to inform prescribing and dispensing practices and to aid in investigations. CURES was established in its current form in 2008 and recently upgraded to “CURES 2.0,” which is now considered a state-of-the-art tool. Prescribers and dispensers of controlled substances are required to obtain a login to access CURES. The vast majority of queries are from these health care personnel seeking to review a patient’s prescription history. This bill will require CURES to offer an additional function that may assist in detecting fraud and abuse.
- Related Legislation. There is a large number of bills introduced this year addressing various aspects of the opioid epidemic, including improvements to CURES, limits on opioid prescribing, higher reimbursement for drug treatment providers, and improved access to naloxone, which can prevent death from overdose.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 10, 2018
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 2086
Author:(Gallagher) – As Amended Ver:April 3, 2018
SUBJECT: Controlled substances: CURES database.
SUMMARY: Allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber in the California Department of Justice (DOJ)’s prescription drug monitoring program (PDMP).
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) § 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC § 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC § 11156)
- Establishes the Controlled Substance Utilization Review and Evaluation System (CURES), a PDMP maintained by the DOJ for the purposes of collecting records of dispensed controlled substances for review by licensed prescribers and dispensers, regulatory investigators, law enforcement, and statistical researchers. (HSC § 11165(a))
- Requires pharmacists and other dispensers to report information to CURES within 7 days relating to prescriptions of Schedule II, III, and IV controlled substances. (HSC § 11165(d))
- Requires health care practitioners in receipt of a federal Drug Enforcement Administration (DEA) certificate providing authorization to prescribe controlled substances, as well as pharmacists, to register for access to the CURES database. (HSC § 11165.1(a))
- Pending certification of readiness by the DOJ, requires certain health care practitioners to consult the CURES database to review a patient’s controlled substance history before prescribing a Schedule II, Schedule III, or Schedule IV controlled substance to the patient for the first time and at least once every four months thereafter if the substance remains part of the treatment of the patient, with certain exceptions. (HSC § 11165.4)
- Requires the DOJ to upgrade CURES to allow health information technology systems that meet certain patient privacy and data security requirements to interoperate with the database, allowing prescribers and dispensers to make queries through their electronic health record applications. (HSC § 11165.1)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC § 11173)
- Enables security printers and prescribers to report stolen or lost prescription pads to the DOJ through CURES. (HSC § 11165.3)
- Provides dedicated funding for the CURES program through an annual license fee of $6 assessed for licensees authorized to prescribe or dispense controlled substances in California. (Business and Professions Code (BPC) § 208)
- Authorizes the DOJ to seek voluntarily contributed private funds from insurers, health care service plans, qualified manufacturers, and other donors for the purpose of supporting CURES. (HSC § 11165.5)
- Allows the DOJ to conduct audits of CURES and its users and issue citations and fines for system misuse. (HSC § 11165.2)
- Requires the CURES database to comply with all applicable federal and state privacy and security laws and regulations and requires the DOJ to establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES. (HSC § 11165(c))
THIS BILL:
- Allows a prescriber to access the CURES database for a list of patients for whom that prescriber is listed as a prescriber in the CURES database.
FISCAL EFFECT: Unknown; this bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
The opioid epidemic is a public health crisis that affects every community. Addressing it will take a multi-pronged approach that includes education, treatment, and prevention. It also includes keeping pills out of the hands of people who shouldn’t have them, and AB 2086 will do this by helping us identify fraudulent prescriptions. AB 2086 will help prevent fraudulent prescriptions of controlled substances by allowing prescribers to request a list of patients for whom they are listed as being the prescriber in the CURES database.
Background. Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a necessarily critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is substantial evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
CURES Database. CURES was first established in 1996 as a “technologically sophisticated” database containing prescription records collected through California’s Triplicate Prescription Program, which provided the DOJ with copies of all Schedule II drug prescriptions. Subsequent legislation made CURES the state’s sole prescription record repository and added Schedule III and IV drugs to the database. In 2008, CURES was upgraded to function as a PDMP, allowing health professionals, regulators, and law enforcement to conduct web-based searches of the system to inform prescribing practices and support investigations.
Budget problems later plagued the database as the elimination of the DOJ’s Bureau of Narcotics Enforcement effectively defunded the CURES program. Users of the system complained that the PDMP offered insufficient client support and was plagued with technical issues. In response, Attorney General Kamala D. Harris sponsored legislation to overhaul the database with revenue newly derived from a $6 license fee for healing arts professionals. The resulting system, commonly referred to as “CURES 2.0,” is considered to be a significantly improved, state-of-the-art tool for addressing the abuse and diversion of opioids and other prescription drugs.
Every dispenser of controlled substances and every health practitioner authorized by the DEA to prescribe controlled substances is required to obtain a login for access to CURES. For each dispensed Schedule II, III, or IV drug, pharmacists are required to report basic information about the patient and their prescription within 7 days. This information is then made available to other system users in a variety of possible contexts. For example, physicians may query a patient’s prescription history prior to writing a new prescription; pharmacists can check the system before agreeing to fill a prescription for a controlled substance; regulators may review a licensee’s prescribing practices as part of a disciplinary investigation; and law enforcement can incorporate a search of the system into a potential criminal case of drug diversion.
Over 50 million prescription records have been uploaded into the system by dispensing pharmacists since the beginning of the CURES program. As of January 1, 2018, 170,422 users had been approved for access to the system. Last year, close to 10 million activity reports had been processed by practitioners, pharmacists, law enforcement, and regulatory users. The vast majority of these searches (over 99%) were queries made by prescribers and dispensers seeking to review a patient’s prescription history as a component of exercising informed clinical judgment before providing access to opioids or other controlled substances.
Access to CURES is limited by a number of state and federal privacy laws. This includes the Health Insurance Portability and Accountability Act (HIPAA), the California Medical Information Act, and the Information Practices Act. Whether law enforcement use of the system implicates the Fourth Amendment’s protections against unreasonable searches remains a topic of debate. In 2017, the Supreme Court of California ruled in Lewis v. Superior Court that privacy interests are justified by the state’s interest in preventing drug diversion and protecting patients.
Beginning six months from a to-be-announced date of certification by the Attorney General, health practitioners will be required to consult the CURES database prior to writing a prescription for a Schedule II, III, or IV drug for the first time, and then at least once every four months as long as the prescription continues to be renewed. Other recently enacted statutes require the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements. As attention to the opioid crisis continues to grow, CURES and other PDMPs are regularly mentioned as powerful tools for curbing the abuse of prescription drugs.
Prescriber Access to Prescription Records. Statute is somewhat nonspecific in regards to how data in CURES may be accessed by authorized users. The DOJ is required to “establish policies, procedures, and regulations regarding the use, access, evaluation, management, implementation, operation, storage, disclosure, and security of the information within CURES.” To date, the majority of CURES access policies are not memorialized in regulations or codified in statute. Access to the database is preceded by acceptance of a user agreement that does outline certain parameters of system misuse. Beyond that, health practitioners logging into CURES are simply required to comply with “all applicable federal and state privacy and security laws and regulations.”
CURES is additionally required by statute generally to “operate under existing provisions of law to safeguard the privacy and confidentiality of patients.” In addition to the federal Health Insurance Portability and Accountability Act (HIPAA) and any constitutional protections of privacy, there are several state statutes specifically believed to apply to CURES. The DOJ has historically interpreted the Information Practices Act as applicable to the database, which governs how state agencies must generally handle personal information. The California Medical Information Act, which limits the disclosure of medical information by health entities, is widely believed to apply to the disclosure of data in CURES. State medical information laws regarding patient access to health records also give individuals a right to receive copies of information about them contained in CURES.
In the past, the DOJ has stated that it does not believe it has statutorily authority to allow health practitioners to request their own physician activity report for purposes of reviewing patients affiliated with them in CURES. This access is desirable to practitioners because it would enable them to identify unknown patients alleging that they had received a prescription from the practitioner’s office, suggesting possible fraud for which the practitioner may be unknowingly held liable. Because there is nothing clearly permitting that this use of the system is permitted within the access parameters that exist within statute, the medical professional community has advocated for clarification.
Current Related Legislation. AB 1751 (Low) would provide a framework for the CURES PDMP to connect with other states that comply with California’s patient privacy and data security standards.
AB 1752 (Low) would add Schedule V drugs to the CURES database and change the requirement for pharmacists to report dispensed prescriptions from seven days to the following business day.
AB 1753 (Low) would limit the number of security printers authorized to manufacture prescription pads and linking uniquely serialized pads with CURES.
AB 2384 (Arambula) would remove barriers to medication-assisted treatment, such as prior authorization requirements and limits on coverage.
AB 2741 (Burke) would limit all opioid prescriptions for minors to a maximum of 5 days, with exceptions, and require a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain written consent prior to writing the prescription.
AB 2859 (Caballero) would increase safe storage practices among parents to prevent access to prescription drugs in the home by children and adolescents.
AB 2487 (McCarty) would add opioid addiction training as a continuing medical education requirement for certain physicians to increase the availability of buprenorphine treatment.
AB 2486 (McCarty) would establish the Opioid Prevention and Rehabilitation Program Fund to treat opioid addiction by providing existing programs the additional funding.
AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance schedules.
AB 1963 (Waldron) would incentivize medical providers to become certified prescribers of medication-assisted treatment by increasing the reimbursement rates for providers who prescribe these drug treatments.
AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions.
AB 2760 (Wood) would require certain prescriptions for opioids to also include a co-prescription for naloxone.
Prior Related Legislation. AB 3042 (Takasugi, Chapter 345, Statutes of 2002) first established CURES as a pilot project operating concurrently with the state’s Triplicate Prescription Program.
SB 151 (Burton, Chapter 406, Statutes of 2003) made CURES the state’s permanent prescription tracking program and added Schedule III drugs to the database.
SB 734 (Torlakson, Chapter 487, Statutes of 2005) created the framework to upgrade the CURES prescription database into a searchable, client-facing PDMP.
AB 2986 (Mullin, Chapter 286, Statutes of 2006) added Schedule IV drugs to the CURES database.
SB 809 (DeSaulnier, Chapter 400, Statutes of 2013) established new healing arts license fees to fund the development and maintenance a new and improved “CURES 2.0” database.
SB 482 (Lara, Chapter 708, Statutes of 2016) mandated that health practitioners consult a patient’s history in CURES prior to prescribing them a Schedule II, III, or IV controlled substance for the first time and then at least once every four months as long as the prescription continued to be renewed.
AB 40 (Santiago, Chapter 607, Statutes of 2017) required the DOJ to facilitate interoperability between health information technology systems and the CURES database, subject to a memorandum of understanding setting minimum security and privacy requirements.
ARGUMENTS IN SUPPORT:
The California Dental Association (CDA) supports AB 2086. According to CDA, the DOJ’s current prohibition on practitioners querying their own prescribing history “makes it difficult for prescribers to identify whether a patient has been presenting fraudulent or forged prescriptions from a health professional who has not actually written a prescription for that patient.” The Medical Association (CMA), also in support of the bill, echoes CDA’s argument, believing the clarification to be an improvement to the CURES database.
The California Police Chiefs Association (Cal Chiefs) also supports the bill. In its letter of support, Cal Chiefs notes that once a practitioner has identified potential cases of fraud, the alleged prescriber should notify local law enforcement. “By allowing prescribers to cross reference their records with the records of CURES they can help save lives by alerting the proper authorities when their signatures have been falsely used.”
ARGUMENTS IN OPPOSITION:
None on file.
REGISTERED SUPPORT:
California Dental Association
California District Attorneys Association
CaliforniaHealth+ Advocates
California Hospital Association
California Medical Association
California Police Chiefs Association
California Society of Anesthesiologists
REGISTERED OPPOSITION:
None on file.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301
Discussed in Hearing
Assembly Floor
Senate Floor
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):